Acrux begins anti-nausea trial
Wednesday, 02 March, 2005
Acrux (ASX:ACR) has commenced dosing in a Phase I clinical trial utilising its MDTS transdermal spray to deliver anti-nausea drug granisetron. The pharmacokinetics trial will compare absorption of the drug, which is used to treat nausea in chemotherapy patients, against that of an oral formulation in six healthy volunteers.
"Prevention of nausea during chemotherapy with a product that does not require injections or tablets would help minimise distress for cancer patients," said Acrux CEO Igor Gonda. Brisbane-based CRO Q-Pharm is conducting the trial in its clinical trials facilities at the Royal Brisbane Hospital for Acrux subsidiary Acrux DDS.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
